Fed’s Powell opens door to potential rate cuts at Jackson Hole
LONDON - Roquefort Therapeutics PLC (LSE:ROQ), a biotech company listed on the Main Market, has disclosed upcoming changes to its board. CEO Ajan Reginald and Non-Executive Director Prof. Sir Martin Evans will resign from their positions effective at the close of business on March 17, 2025. Dr. Darrin M Disley OBE will assume the role of Interim Managing Director from the same date.
Disley, a Non-Executive Director at Roquefort, is recognized for his leadership at Horizon Discovery (NASDAQ:WBD), a gene editing firm he guided from inception in 2007 to a successful IPO and subsequent global expansion. His tenure culminated in the company’s acquisition by PerkinElmer (NYSE:RVTY) in 2021 for £296 million.
The departures of Reginald and Evans are part of a strategic transition as Roquefort completes the first phase of its business strategy, which includes the trade sales of its subsidiaries Lyramid Pty Ltd and Oncogeni Limited. Reginald will continue as a consultant for Roquefort and as Chairman of Oncogeni to facilitate the subsidiary’s sale to The Nations Trust Holding. He has waived his service agreement’s notice period to expedite the transition.
Stephen West, Chairman of Roquefort Therapeutics, expressed gratitude to Reginald for his service and welcomed Disley’s appointment. West anticipates collaborating with Disley on the company’s future strategy, building on the leadership changes and the completion of the subsidiary transactions.
This announcement contains inside information as per the UK version of the market abuse regulation, which is part of the United Kingdom (TADAWUL:4280) domestic law following the European Union (Withdrawal) Act 2018. The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.